Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells

Cancer Biology and Therapy

Volumn 10, Issue 9, 2010, Pages 885-892

  Metwalli, Adam R ^a   Khanbolooki, Sanaz ^a   Jinesh, Goodwin ^a   Sundi, Debasish ^a   Shah, Jay B ^a   Shrader, Marissa ^a   Choi, Woonyoung ^a   Lashinger, Laura M ^a   Chunduru, Srinivas ^b   McConkey, David J ^a   McKinlay, Mark ^b   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TetraLogic Pharmaceuticals   (United States)

Author keywords

Bladder cancer; Chemotherapy; IAP antagonist; Smac mimetic; TRAIL

Indexed keywords

CASPASE; CASPASE 3; PROCASPASE 3; PROCASPASE 7; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DNA FRAGMENTATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; UROGENITAL TRACT CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; OLIGOPEPTIDES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; URINARY BLADDER NEOPLASMS; UROTHELIUM; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 78549284338     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.9.13237     Document Type: Article

References (36)

1. Kerr JF. Shrinkage necrosis: a distinct mode of cellular death. J Pathol 1971; 105:13-20.
2. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-57.
3. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284:555-6.
4. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-6.
5. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu Rev Biochem 1999; 68:383-424.
6. Wolf BB, Schuler M, Echeverri F, Green DR. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 1999; 274:30651-6. (Pubitemid 129576806)
7. Makin G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000; 301:143-52.
8. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-62.
9. Nguyen JT, Wells JA. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc Natl Acad Sci USA 2003; 100:7533-8.
10. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3:17-22.
11. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13:239-52.
12. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-10.
13. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406:855-62.
14. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996; 379:349-53.
15. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408:1008-12. (Pubitemid 32101651)
16. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002; 277:44236-43.
17. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004; 305:1471-4.
18. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005; 24:7381-8.
19. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004; 64:3006-8. (Pubitemid 38581397)
20. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through downregulation of nuclear factor-kappaB and nuclear factorkappaB-regulated gene products in IFNalpha-sensitive and IFNalpha-resistant human bladder cancer cells. Mol Cancer Ther 2007; 6:1022-30.
21. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131:682-93.
22. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
23. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005; 65:4902-8.
24. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-8.
25. Gomez-Benito M, Balsas P, Bosque A, Anel A, Marzo I, Naval J. Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett 2005; 579:6217-22. (Pubitemid 41546271)
26. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004; 64:8973-9.
27. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001; 166:1300-4.
28. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer druginduced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8:808-15.
29. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, et al. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 2001; 142:370-80.
30. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004; 11:309-16. (Pubitemid 38586086)
31. McManus DC, Lefebvre CA, Cherton-Horvat G, et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004; 23:8105-17.
32. Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo2L. Blood 2005; 106:3474-82.
33. Kocak H, Oner-Iyidogan Y, Kocak T, Oner P. Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Biochem 2004; 37:673-8.
34. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 2004; 64:3386-90.
35. Mehmut M, Takeda K, Abe M, Ogata H, Hirose S, Okumura K, et al. Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guerin treatment. Urol Int 2005; 75:80-7. (Pubitemid 41022600)
36. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFNalpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 1999; 162:2399-405.